Adaptimmune Therapeutics plc (Nasdaq: ADAP) announced that the European Commission has designated the company’s NY-ESO SPEAR® T-cell therapy as an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE